Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 108 of the 114 references it cites were found in a registry or an index; 71 of the 125 sources its claims cite were checked for support.

The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease

Open access

Abstract

Psychiatric disorders are 1.5 to 2 times more prevalent in persons with inflammatory bowel disease (IBD) than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression. Rates are even higher when considering mental health symptoms, as nearly one-third of persons with IBD experience elevated anxiety symptoms and one-quarter experience depression symptoms. Rates of these symptoms were much higher during periods of disease activity, more common in women than men, and more common in Crohn's disease than ulcerative colitis. There is robust evidence of the detrimental effects of comorbid depression and anxiety on the subsequent course of IBD based on longitudinal studies tracking outcomes over time. However, psychiatric disorders and IBD have bidirectional effects, with each affecting risk of the other. Elevated mental health concerns have been consistently associated with greater healthcare utilization and costs related to IBD. There is some signal that low resilience in adolescence could be a risk factor for developing IBD and that enhancing resilience may improve mental health and intestinal disease outcomes in IBD. Psychological therapies used to treat anxiety and depression occurring in the context of IBD have been shown to significantly improve the quality of life for persons with IBD and reduce anxiety and depression. There is less evidence in regard to the impact of psychotropic medications on mental health or disease outcomes in persons with IBD. There is consensus, however, that mental health must be addressed as part of comprehensive IBD care for children and adults. © 2023 The Author(s). Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.

Overview

CoChat Summary

## TL;DR

This review summarizes evidence that mental health disorders and symptoms are more common in people with IBD, are bidirectionally linked with worse IBD disease course, and are associated with higher healthcare use and costs. It also concludes that integrated multidisciplinary care and psychological therapies are the most supported approaches, while evidence for psychotropic medications and some other interventions remains limited.

## Key findings

  • Psychiatric disorders were reported to be 1.5–2 times more prevalent in persons with IBD than in the general population, with pooled prevalence estimates of 21% for clinical anxiety and 15% for depression.
  • Symptom burden is also high: nearly one-third of persons with IBD experience elevated anxiety symptoms and one-quarter experience depression symptoms; rates were higher during disease activity, more common in women, and more common in Crohn’s disease than ulcerative colitis.
  • Mental health concerns were linked to worse IBD outcomes. For example, in the Swiss IBD Cohort Study (n = 1,973), elevated depressive symptoms were associated with recurrence of active disease (aHR 3.55), surgery (aHR 2.16), primary nonresponse to therapy (aHR 1.91), and systemic corticosteroid therapy (aHR 1.58).
  • Psychological therapies improved outcomes: CBT and mindfulness were reported to significantly improve quality of life and reduce anxiety/depression, with one RCT of IBD-tailored CBT reporting benefit for moderate-to-severe presentations (depression d = 0.48; anxiety d = 0.58); a mindfulness trial reported immediate post-treatment effects ranging from d = 0.56 to 1.27 and six-month effects of d = 0.45 to 1.38.

## Methods

  • This paper is a narrative review / impact-report chapter synthesizing prior epidemiologic studies, cohort studies, systematic reviews/meta-analyses, and intervention studies on mental health and IBD.
  • It draws on evidence from adults, children, and adolescents with IBD, including population-based databases, cohort studies, randomized controlled trials, and systematic reviews.
  • The main analysis is qualitative synthesis of published evidence; the paper does not report a new primary study design of its own.

## Limitations

  • The paper states that psychotropic medications have less evidence for effects on mental health or IBD outcomes than psychological therapies, and that there is little data on efficacy directly in IBD.
  • The paper notes that very few studies have evaluated resilience and self-efficacy over time in IBD, limiting directionality.
  • Evident from the text: much of the evidence summarized is from observational studies, small pilots, or heterogeneous samples, so causal conclusions are limited; the paper also explicitly notes some findings are based on uncontrolled comparator samples or studies with small sample size.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/jcag/gwad012

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

59 Valid · 3 Not valid · 43 Not checked · 7 Own results and interpretations

72 more claims · 36 with their cited sources checked

Create a free account to see all 112 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 5
  • It may state two separate claims as one. 31

Create a free account to see these claims.

Citations

Cites

Show all 114 references

Research works printed but not linked: 3

  1. Canada S, 2013, Canadian Community Health Survey: Mental Health, 2012
  2. Hungund, 2022, Psychological well-being of adolescents: Association with personality, J Positive School Psychol, 7, 6040
  3. Administration UFaD, 2011, FDA Drug Safety Communication: Abnormal Heart Rhythms Associated with High Doses of Celexa (Citalopram Hydrobromide)

Cited by

See all 30

Metadata

Authors
Graff, L. A., Geist, R., Kuenzig, M. E., Benchimol, E. I., Kaplan, G. G., Windsor, J. W., Bitton, A., Coward, S., Jones, J. L., Lee, K., Murthy, S. K., Peña-Sánchez, J.-N., Targownik, L. E., Jannati, N., Jones May, T., Akhtar Sheekha, T., Davis, T., Weinstein, J., Dahlwi, G., Im, J. H. B., Amankwah Osei, J., Rohatinsky, N., Ghandeharian, S., Goddard, Q., Gorospe, J., Gertsman, S., Louis, M., Wagner, R., Brass, C., Sanderson, R., & Bernstein, C. N.
Affiliations
  • University of Manitoba (CA)
  • University of Toronto (CA)
  • Hospital for Sick Children (CA)
  • University of Calgary (CA)
  • McGill University Health Centre (CA)
  • Dalhousie University (CA)
  • Crohn's and Colitis Canada (CA)
  • University of Ottawa (CA)
  • University of Saskatchewan (CA)
  • Mount Sinai Hospital (CA)
  • Division of Gastroenterology and Hepatology, University Health Network, University of Toronto , Toronto, Ontario , Canada
  • Department of Community Health and Epidemiology, University of Saskatchewan , Saskatoon, Saskatchewan , Canada
  • King Abdulaziz University (SA)
  • McMaster University (CA)
  • University of Alberta (CA)
  • Muskoday First Nation , Saskatchewan , Canada
  • James Smith Cree Nation , Saskatchewan , Canada
Corresponding author
Bernstein, Charles N
Venue
Journal of the Canadian Association of Gastroenterology
Published
2023-09-01
Volume
6
Issue
Supplement_2
Pages
S64-S75
ISSN
  • 2515-2084 (ISSN-L)
  • 2515-2092
OpenAlex
W4386457006
Cited by
30
References
114
Citations by year
2026: 14 · 2025: 8 · 2024: 7 · 2023: 1
FWCI
1.15
Type
journal article
Language
en
Open access
Locations
  • Journal of the Canadian Association of Gastroenterology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • AbbVie Corporation
  • Janssen Canada
  • Pfizer Canada
  • Bristol-Myers Squibb Canada
  • Amgen Canada
  • Takeda Foundation
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
inflammatory bowel disease, mental health, depression, anxiety, psychiatric comorbidity, Crohn's disease, ulcerative colitis, disease activity, health care utilization, health care costs, resilience, psychotherapy, psychotropic drugs, quality of life, bidirectional comorbidity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1093/jcag/gwad012
The paper
Graff, L. A., Geist, R., Kuenzig, M. E., Benchimol, E. I., Kaplan, G. G., Windsor, J. W., Bitton, A., Coward, S., Jones, J. L., Lee, K., Murthy, S. K., Peña-Sánchez, J.-N., Targownik, L. E., Jannati, N., Jones May, T., Akhtar Sheekha, T., Davis, T., Weinstein, J., Dahlwi, G., . . . Bernstein, C. N. (2023). The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology. https://doi.org/10.1093/jcag/gwad012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.